FDA Clearance Tracker · P180029
LOTUS Edge Valve System
Last checked: Nov 20, 2026Latest source record: Apr 23, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Apr 23, 2019
Approval withdrawn
Time to decision
252 days
Received Aug 14, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P180029
- Device name
- LOTUS Edge Valve System
- Applicant
- Boston Scientific Corporation
- Applicant location
- Marborough, MA
- Received
- Aug 14, 2018
- Decided
- Apr 23, 2019
- Decision
- Approval withdrawn
- Supplements
- 28 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the LOTUS Edge Valve System. The device is indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis (aortic valve area [AVA] of <= 1.0 cm2 or index of <= 0.6 cm2/m2) who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality >= 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical comorbidities unmeasured by the STS risk calculator).
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code NPT. The earliest in FDA's data is P100041, decided Nov 2, 2011.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Boston Scientific Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- SpaceOAR Flex System510(k)
K262151 · Decided Sep 11, 2026 · 78 days after receipt
Device type: Hydrogel Spacer (OVB) · Radiology & Imaging
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.